Insulet Begins Pivotal Study of Fully Closed-Loop Omnipod for Type 2
Insulet has enrolled its first participant in its EVOLVE trial testing an automated system designed to eliminate mealtime bolus announcements for people with type 2 diabetes.
FDA Expands Tzield to Children Age 1+ to Delay Type 1 Diabetes
Sanofi's disease-modifying therapy can now be used in children as young as 1 year old, opening a new window to delay type 1 diabetes progression in the youngest patients.
Sana Biotechnology and Mayo Clinic Team Up for Potential Type 1 Diabetes Cure
The two have partnered to develop SC451, an investigational cell therapy aiming to restore the body’s ability to regulate glucose and eliminate the need for both insulin and immunosuppressive therapy.
MiniMed's Simplera Sync CGM is Coming to Canada This Year
Canadian MiniMed 780G users will have a new CGM option with the Simplera Sync, a smaller, calibration-free sensor designed for easier diabetes management.
Dexcom Highlights CGM Advances and Product Roadmap at ATTD 2026
During the conference, Dexcom showcased upcoming device updates, new platform features, and future innovations designed to expand and enhance its CGM ecosystem.
Glooko to Integrate Roche’s Accu-Chek SmartGuide CGM in Latest Partnership
The collaboration allows Accu-Chek's CGM data to flow into the Glooko platform, giving care teams a single dashboard to review glucose trends in select European markets.
Promising Results for Omnipod’s Type 2 Fully Closed-Loop Algorithm
Results from the EVOLUTION 2 trial presented at ATTD showed 68% time in range using a fully closed-loop system—with no mealtime boluses and minimal time below range.
